Related Experiment Video
Updated: Apr 4, 2026
Establishment and Culture of Patient-Derived Breast Organoids
Published on: February 17, 2023
Long-term culture of patient-derived pheochromocytoma organoids
Marit F van den Berg1, Elpetra P M Timmermans-Sprang1, Jan Zethof2
1Department Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands.
Introduction:
Pheochromocytomas (PCCs) are rare neuroendocrine tumors with limited treatment options once metastasized. Progress toward effective therapies has been hindered by their rarity, disease heterogeneity, and lack of representative preclinical models. Organoids are three-dimensional, self-renewing structures that recapitulate key features of their tissue of origin, providing valuable platforms for disease modeling, drug screening, and personalized medicine. This study aimed to establish and characterize patient-derived organoid cultures of PCCs.
Methods:
Tumor tissue from two patients undergoing surgery for PCC was collected to generate organoid cultures. Organoids were expanded under growth factor-enriched conditions and characterized by histology, immunohistochemistry, immunofluorescence, gene expression via qPCR, and metanephrine quantification via LC-MS/MS.
Results:
Both cultures could be maintained for multiple weeks and serially passaged, with PCC1 maintained in culture for 129 days and expanded up to passage 3 (passaged every 34-53 days), and PCC2 cultured for 139 days, reaching passage 2 (passaged every 63 days). At the protein level, organoids expressed both stem/progenitor markers (nestin, vimentin, SOX10) and chromaffin differentiation markers (synaptophysin, CD56), although expression of the latter was markedly reduced compared to primary tumor tissue. Metanephrine production confirmed initial secretory activity, but hormone production declined over time.
Conclusions:
This pilot study demonstrates that patient-derived organoid cultures can be established from human PCCs and maintained with serial passaging. In early stages, these organoids maintain key phenotypic and functional traits of their original tumors; however, these features diminish over time, consistent with a progressive loss of chromaffin differentiation and/or expansion of less differentiated cell populations. Further optimization is required to improve their long-term proliferation and differentiation potential. Together, these findings provide a proof-of-concept for the development of patient-derived PCC organoid models, which may ultimately serve as a platform for studying PCC biology and for future exploration of personalized therapeutic approaches.
Insights
Patient-derived organoid cultures were successfully established from pheochromocytomas (PCCs), offering a new model for studying these rare tumors. While early organoids mimic tumor traits, further optimization is needed for long-term use in personalized medicine.
Area of Science:
- Oncology
- Endocrinology
- Stem Cell Biology
Background:
- Pheochromocytomas (PCCs) are rare neuroendocrine tumors with limited treatment options for metastatic disease.
- Disease heterogeneity and lack of representative preclinical models hinder therapeutic progress.
- Organoids offer a promising 3D model system for recapitulating tissue features and advancing personalized medicine.
Purpose of the Study:
- To establish and characterize patient-derived organoid cultures from human pheochromocytomas (PCCs).
- To assess the potential of these organoids as models for PCC biology and personalized therapeutic strategies.
Main Methods:
- Patient-derived tumor tissues were used to generate organoid cultures.
- Organoids were cultured under specific growth factor conditions.
- Characterization involved histology, immunohistochemistry, immunofluorescence, gene expression (qPCR), and metanephrine quantification (LC-MS/MS).
Main Results:
- Organoid cultures were successfully maintained and serially passaged for over 100 days.
- Organoids expressed stem/progenitor and some chromaffin differentiation markers.
- Initial secretory activity (metanephrine production) was confirmed, but hormone production decreased over time.
Conclusions:
- Patient-derived PCC organoid cultures can be established and serially passaged.
- Early-stage organoids retain key tumor traits, but differentiation markers diminish over time.
- These organoids provide a proof-of-concept for PCC modeling and future personalized therapeutic exploration.
